|
What is the type of my study, case control or retrospective cohort?
|
|
6
|
130
|
January 27, 2023
|
|
Effectiveness of Paxlovid a retrospective study
|
|
5
|
184
|
January 11, 2023
|
|
Justification of sample size for the generation of a prediction model
|
|
7
|
439
|
January 11, 2023
|
|
Should we account for competing risk when estimating incidence rate?
|
|
3
|
223
|
January 5, 2023
|
|
Precision-based sample size calculation for one survival curve
|
|
3
|
292
|
November 16, 2022
|
|
Conceptual question about survival analysis vs logistic regression: when is one more appropriate than the other?
|
|
16
|
10826
|
October 27, 2022
|
|
Background to PFS endpoint
|
|
19
|
5195
|
October 6, 2022
|
|
Method to obtain optimal cut-off point for survival outcomes
|
|
3
|
468
|
October 1, 2022
|
|
Could cardiovescular risk nomogram be supirior than the Framingham Risk Score? If so, what could be the reasons?
|
|
0
|
233
|
September 20, 2022
|
|
Elastic net model for non-linear relationship?
|
|
2
|
1908
|
July 26, 2022
|
|
Intervention with early survival benefit, questionable long term harm
|
|
8
|
1588
|
May 26, 2022
|
|
Schoenfeld Residuals
|
|
1
|
1648
|
May 23, 2022
|
|
Comparing non-nested models on the same data
|
|
4
|
2663
|
May 13, 2022
|
|
Should I impute person-time before conducting proportional hazards analysis?
|
|
7
|
1445
|
May 8, 2022
|
|
Stratification on a variable involved in an interaction term
|
|
3
|
1192
|
May 4, 2022
|
|
Validation of cox model
|
|
4
|
3790
|
May 2, 2022
|
|
Cutpoint for Estimation of Prognostic value of a continuous Marker
|
|
5
|
1637
|
May 2, 2022
|
|
How should I compare crossing survival curves?
|
|
5
|
2932
|
April 28, 2022
|
|
Is logistic regression or survival analysis most appropriate in this case?
|
|
1
|
1070
|
April 28, 2022
|
|
Statistical power estimation for a time-dependent covariate in Cox (proportional hazards) regression
|
|
0
|
986
|
April 19, 2022
|
|
Propensity score weighting and competing risks
|
|
2
|
1923
|
March 30, 2022
|
|
How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
1372
|
March 6, 2022
|
|
RMS Case Study in Cox Regression
|
|
1
|
13679
|
September 17, 2021
|
|
Hazard ratio plots with non-linear & time-varying effects in R
|
|
28
|
29660
|
September 19, 2020
|
|
How to use RCS in mixed effects cox regression
|
|
3
|
2855
|
December 10, 2021
|
|
Kaplan-Meier: SE for absolute difference in time-point survival
|
|
13
|
2747
|
October 30, 2021
|
|
How can I determined the best cutoff for survival ROC
|
|
1
|
1864
|
October 10, 2021
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
15450
|
October 8, 2021
|
|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
2
|
4311
|
September 22, 2021
|
|
RMS Case Study in Parametric Survival Modeling
|
|
0
|
10460
|
September 17, 2021
|